Two Rabbit Monoclonal Antibodies Released for Cancer Diagnosis

A provider of cancer diagnostic solutions announced the addition of two new antibodies, Anti-CK 8/18 and Anti-TdT, to a portfolio of high-quality reagents, instruments, and software.

Anti-CK 8/18 is the first rabbit monoclonal antibody cocktail for cytokeratin 8/18 (CK 8/18) available from a major pathology provider. It is used by pathologists to stain CK 8/18 in tissue samples and thereby help classify tumors of unknown origin. Keratins are one of the most potent epithelial differentiation and tumor markers in cancer diagnostics.


Anti-TdT, also a rabbit monoclonal antibody, is used to help classify lymphoma and leukemia by staining terminal deoxynucleotidyl transferase (TdT) in tissue samples. In immunohistochemistry, antibodies to TdT can be used to demonstrate the presence of pre-T and pre-B cells and multipotent hematopoietic stem cells that possess the antigen.

Both antibodies are available from Dako now as 1.0 mL concentrates and 12 mL (60 tests).

Dako (Glostrup, Denmark) released the antibodies Anti-CK 8/18 and Anti-TdT, which provide good specificity and sensitivity, and have been evaluated and accepted by pathologists. Both antibodies provide optimal staining results with the FLEX ready-to-use Dako solutions. FLEX ready-to-use is a plug-and-play solution consisting of pre-diluted antibodies, a visualization system, and optimized validated protocols developed in collaboration with pathologists. The protocols are developed to take into account pre-analytical variations and different ways of processing and handling tissue samples, ensuring optimal staining results for pathology labs.

Hans Christian Pedersen, global product manager, Dako said, "With the FLEX RTU solution, it takes less time for a lab to validate new antibodies for routine diagnostic use. FLEX ready-to-use antibodies are helping labs get high-quality results from day one."

"We are pleased to add these two high-quality antibodies to our comprehensive offering to pathologists around the world," said Britt Meelby Jensen, vice president of marketing and pathology sales in Agilent's diagnostics and genomics business. "One of our goals is to constantly establish new quality benchmarks within IHC reagents."

Agilent Technologies Inc. (Santa Clara, CA, USA) is a measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics, and communications. In 2012, it acquired Dako a provider of reagents, instruments, software, and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients.

Related Links:
Dako
Agilent